A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and Vacaville
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish bioequivalence of paliperidone ER tablets
manufactured at Gurabo as compared to paliperidone ER tablets manufactured at Vacaville,
administered as a single dose of 12 mg under fasted conditions to healthy male volunteers,
and to assess the safety and tolerability of both formulations.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.